INmune Bio (NASDAQ:INMB - Get Free Report) is expected to post its Q1 2025 earnings results after the market closes on Thursday, May 8th. Analysts expect INmune Bio to post earnings of ($0.43) per share for the quarter.
INmune Bio (NASDAQ:INMB - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.14. On average, analysts expect INmune Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
INmune Bio Trading Down 5.7 %
Shares of INmune Bio stock traded down $0.43 on Tuesday, hitting $7.12. 306,034 shares of the company traded hands, compared to its average volume of 252,975. INmune Bio has a 52 week low of $4.32 and a 52 week high of $11.47. The company has a market cap of $163.65 million, a PE ratio of -3.27 and a beta of 1.63. The stock's 50 day moving average price is $7.74 and its 200-day moving average price is $6.83.
Analysts Set New Price Targets
INMB has been the subject of a number of analyst reports. Maxim Group upped their price objective on INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Rodman & Renshaw started coverage on shares of INmune Bio in a report on Tuesday, January 28th. They issued a "buy" rating and a $23.00 price target on the stock. Scotiabank boosted their price objective on shares of INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, February 11th. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $22.80.
View Our Latest Report on INmune Bio
About INmune Bio
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Featured Stories
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
